ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
IDMC Concluded Lynparza Trial Crossed Superiority Boundary for Invasive Disease-Free Survival
February 20, 2021The OlympiA Phase III trial for AstraZeneca and MSD’s Lynparza will move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee (IDMC). -
Lynparza crosses superiority boundary for invasive disease-free survival at interim analysis
February 19, 2021The OlympiA trial will conduct its primary analysis early, after the Independent Data Monitoring Committee found it met its primary endpoint in BRCA mutated early breast cancer patients.
Pharma Sources Insight January 2025
